COMPARE
CRDFvsSPRY
Cardiff Oncology, Inc. vs ARS Pharmaceuticals, Inc. — head-to-head fundamental comparison across 8 metrics.
METRIC-BY-METRIC BREAKDOWN
| METRIC | CRDF | SPRY |
|---|---|---|
| Total Score | 20 HIGH RISK | 92 EXCELLENT |
| Revenue Growth (YoY) Growth · 20% | 0 | 100 |
| Gross Margin Quality · 15% | 0 | 100 |
| Cash Runway Stability · 20% | 9 | 100 |
| Debt / Equity Stability · 10% | 99 | 100 |
| Price / Sales Valuation · 10% | 0 | 46 |
| Rule of 40 Quality · 10% | 0 | 100 |
| Insider Ownership Governance · 10% | 45 | 78 |
| Share Dilution (12M) Governance · 5% | 83 | 95 |
SCORE TREND
ANALYSIS
CRDF (Cardiff Oncology, Inc.) scores 20 overall, earning a "HIGH RISK" grade, while SPRY (ARS Pharmaceuticals, Inc.) scores 92 with a "EXCELLENT" grade. SPRY leads by 72 points in our 8-metric fundamental analysis.
The largest gap between these two stocks is in revenue growth, where SPRY outscores its peer by 100 points. Both companies operate in the Healthcare sector, and investors should consider these fundamental differences alongside broader market conditions and their own risk tolerance.
SmallCap Scanner scores are calculated from publicly available financial data and are updated monthly. Scores reflect fundamental quality, not price momentum. This comparison is for research purposes only and does not constitute financial advice. Past performance and current fundamentals may not predict future results.
RELATED COMPARISONS· Healthcare